Chronic Wounds and High Risk Surgical Incisions Successfully Treated with Spiracur’s Ultraportable Negative Pressure Wound Therapy System
Research Presented at SAWC Highlights Value of Spiracur’s Proprietary SNaP System for Optimized Healing
SUNNYVALE, Calif., September 24, 2013 – Spiracur Inc., developer of the only mechanically powered advanced wound care solution with the proven efficacy of Negative Pressure Wound Therapy (NPWT), today announced four new clinical abstracts substantiating the viability of the SNaP® Wound Care System for the successful treatment of chronic and acute wounds, including those in anatomically challenging locations, and improvement to quality of life.
These abstracts, as well as a breakout session on the advanced treatment of difficult wounds using the SNaP System and other NPWT devices, will be presented during the Symposium for Advanced Wound Care (SAWC) Fall Conference, Sept. 27-29, in Las Vegas, Nev. The SAWC is the premier interdisciplinary wound care program and the largest annual gathering of wound care clinicians in the United States.
The company also announced the publication of a new guidance document offering expert recommendations for clinicians on the appropriate use of mechanically powered negative pressure wound therapy (MPNPWT) for treating patients’ wounds. A panel of 10 wound care specialists convened to review clinical literature, discuss their extensive experience working with the SNaP System, and key situations pertaining to use of NPWT and MPNPWT. The outcome is a clinical guide designed to help physicians in the decision-making process for MPNPWT.
“The abstracts and breakout session, coupled with the new clinical guidelines, have important implications for use of the SNaP System and our suite of wound care solutions for the successful treatment of chronic and acute wounds including those in challenging anatomical locations and high risk surgical incisions,” said Linda LaMagna, vice president of global marketing for Spiracur Inc. “With Medicare reimbursement covering NPWT delivered by a mechanically-powered device in wound care clinics and physician offices, the SNaP System is now more widely available as an effective, off-the-shelf solution clinics and physicians can offer their patients earlier in the wound care healing process.”
Jodi L. Walters, DPM, director of Podiatry Research, Southern Arizona VA Health Care System, Tucson, Ariz., assistant professor, University of Arizona, and Diplomate, American Board of Podiatric Surgery, will present a clinical abstract entitled, “Use of an Ultraportable Negative Pressure Wound Therapy Platform for Optimized Healing of a High Risk Surgical Incision and Chronic Ulceration in a Patient with Spina Bifida.” The abstract describes a 22-year-old college student with a history of Spina Bifida, chronic pain and chronic right foot ulceration with suspected clinical osteomyelitis. He suffered from an infection and a non-healing ulceration that existed for over three-and-a-half years. The patient was treated with the ciSNaP® for use on the closed incision followed by use of the SNaP System for standard NPWT. The patient’s wound healed rapidly, enabling him to quickly return to active college life, and he remains completely healed after four months.
“Use of both the ciSNaP and the SNaP Systems successfully treated a young, high-risk patient,” said Dr. Walters. “This patient’s quality of life had been seriously compromised for a long time due to his chronic wound and infection, resulting in missed classes; however, once we began our treatment regimen, he was completely healed in just over two week’s time.
“Use of the ultraportable SNaP system for this case study has shown to be as effective as the electrically powered comparator, and it is indicated to be an effective primary treatment option for chronic, non-healing ulcers,” continued Dr. Walters.
A second abstract entitled, “Advances for Negative Pressure Wound Therapy in Challenging Anatomic Locations,” will be presented by Gary Rothenberg, DPM, CDE, CWS, director of Residency Training and attending podiatrist at the Miami Veterans Affairs Healthcare System. The abstract describes utilization of NPWT on a wound that otherwise would have been difficult to seal without the SNaP SecurRing™ Hydrocolloid. Spiracur’s SecurRing is designed to facilitate fast and easy applications of the SNaP System on uneven skin surfaces or wounds in challenging locations.
“The SecurRing Hydrocolloid is an ideal solution for our clinic because it makes dressing applications faster and easier on a large number of our patients suffering from DFUs, ray amputations and plantar wounds,” said Dr. Rothenberg. “When using the SecurRing Hydrocolloid, fewer accessories are required and less time is needed to get a seal. In addition, by using it with the SNaP Dressing, we can now apply NPWT in challenging anatomic locations, which would not have been previously considered.”
Spiracur is recognized for creating a new category of chronic and acute wound management solutions. Several clinical studies have been published supporting the SNaP Wound Care System as an effective alternative to powered NPWT, including a comparative Randomized Controlled Trial that also showed the powerful, small device makes a positive difference in patients’ quality of life. The SNaP device, which does not require batteries or electricity, is now reimbursed by Medicare in wound care centers and physician offices.
About Spiracur Inc.
Spiracur Inc., headquartered in Sunnyvale, Calif., is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford University Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System for the treatment of chronic and acute wounds, is the result of patient and clinician feedback that current negative pressure wound therapies were too cumbersome. The company’s ciSNaP Closed Incision System with proprietary controlled tension relief is designed to improve healing of high-risk surgical incisions. Both devices have been cleared by the U.S. Food & Drug Administration (FDA) and have received CE Mark approval. Spiracur’s proprietary mechanically powered technology does no require batteries or electricity to operate. For more information, please visit http://spiracur.com.
Steve Van Dick
Spiracur, Spiracur logo, SNaP, ciSNaP and SNaP & Design are registered trademarks of Spiracur Inc. SecurRing is a trademark of Spiracur Inc.